
    
      This study is a multi-center, Randomized, Open-label and phase IV clinical trial that
      evaluates the efficacy and safety after conversion to TacroBell SR cap. or TacroBell cap.
      administration for 24 weeks in renal transplant patients undergoing maintenance therapy with
      Reference Tacrolimus.
    
  